Report
Grifols B : Q2 EBITDA in line, earnings notably below. FY 2024 guidance reiterated
>Top-line momentum improves sequentially on everything but Biopharma - Sales grew by +9% or +9% cc (vs +6% cc in Q1) to € 1.8bn, broadly in line with our numbers and the consensus. Sales momentum improved sequentially yet is mostly explained by Bio Supplies (+93%cc in Q2 vs -25% in Q1) and Diagnostic is returning to positive growth territory (+1%cc vs -8% in Q1) while Biopharma lost some momentum vs the previous quarter (+8%cc vs +9% in Q1). Biopharma posted +9% y-o-...
Underlying
Grifols S.A. Pref Class B
Provider
Oddo BHF
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Juan Ros-Padilla
Other Reports on these Companies
Other Reports from Oddo BHF
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.